Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "Tariq Ahmad" Clear advanced filters

  • Mineralocorticoid-receptor antagonists (MRAs) have been shown to reduce adverse cardiovascular outcomes in high-risk patients with ST-segment elevation myocardial infarction (STEMI). Preliminary data suggest that MRAs might improve natriuretic-peptide profiles in patients with STEMI who do not have heart failure, but their clinical efficacy in this patient population requires further study.

    • Tariq Ahmad
    • Matthew T. Roe
    News & Views
    Nature Reviews Cardiology
    Volume: 11, P: 440-442

  • Molecular biomarkers could provide a window into the pathophysiology of chronic heart failure, potentially improving our ability to predict adverse outcomes, provide novel drug targets, and even help gauge therapeutic efficacy. In this Review, Ahmad et al. examine some emerging biomarkers of the biomechanical stretch, inflammation, ventricular remodeling, myocardial injury, and renal dysfunction that occur in chronic heart failure, and discuss their potential role within a multimarker-based strategy.

    • Tariq Ahmad
    • Mona Fiuzat
    • Christopher O'Connor
    Reviews
    Nature Reviews Cardiology
    Volume: 9, P: 347-359

  • Evidence is increasing that genetic variation between patients underlies the considerable variability in their response to antiplatelet agents, and, therefore, in clinical outcomes. Drs Ahmad, Voora, and Becker review the genetic loci that seem to have a role in determining platelet response; genes that are involved in the absorption, metabolic activation, and biological activity of aspirin and clopidogrel. Finally, they discuss, in the context of ongoing clinical trials, the merits and potential dangers of using commercial genetic testing and pharmacogenetics to personalize antiplatelet therapy to individual patients.

    • Tariq Ahmad
    • Deepak Voora
    • Richard C. Becker
    Reviews
    Nature Reviews Cardiology
    Volume: 8, P: 560-571